Cancer Chemotherapy Reports

Prieur, D.J., Young, D.M., Davis, R.D., Cooney, D.A., Homan, E.R., Dixon, R.L. and Guarino, A.M. (1973). Procedures for preclinical toxicologic evaluation of cancer chemotherapeutic agents Protocols of the laboratory of toxicology. Cancer Chemotherapy Reports, Part 3, 4 1-30. 

Jackson L, Kofman S, Weiss A, Brodovsky H. Aristolochic Acid (NSC-50413) Phase I Clinical Study. Cancer Chemotherapy Reports 1964 35-37... 

In addition to technical reports, the National Institutes of Health issue several other publications. One of these is the Journal of the National Cancer Institute which publishes not only a large part of the work done at the National Cancer Institute but also research in many other institutions in the U.S. and other countries. It is available from GPO at 20 a year for 12 issues. Another publication is the Psychopharmacology Service Center Bulletin which is distributed at irregular intervals by the Psychopharmocology Service Center, National Institute of Mental Health, Bethesda 14, Md. It is issued for information purposes to investigators interested in psychopharmacology. Two other publications of NIH are Cancer Chemotherapy Reports and Cancer Chemotherapy Abstracts which may be obtained from National Cancer Institute, Publication Office, Room 213 Robin Building, Bethesda 14, Md. 

Craig, W.A., Evenson, M.A. Ramgopal, V. (1976) The effect of uremia, cardiopulmonary bypass and bacterial infection on serum protein binding. In The Effect of Disease States on Drug Pharmacokinetics, (ed., L.Z. Benet) pp. 125-136. American Pharmaceutical Association, Academy of Pharmaceutical Sciences Washington DC. Dedrick, R.L., Bischoff, K.B. Zaharko, D.S. (1970) Interspecies correlation of plasma concentration history of methotrexate (NSC-740). Cancer Chemotherapy Reports, (Part 1), 54, 95-101. 

Zubrod, C.G. Schepartz, S. Leiten, J. Endicott, K.M. Carrese, L.M. Baker, C.E. Cancer Chemotherapy Reports October 1996, 50 (7) DHEW Washington, DC, 1968. Rate of Development of Anticancer Drugs by the National Cancer Institute and the U.S. Pharmaceutical Industry and the Impact of Regulation. Final Report for the National Cancer Institute University of Rochester Medical Center New York, 1981 40. 

Dedrick, R.L., Bishoff, K.B. and Zaharko, D.S. (1970) Interspecies correlation of plasma concentration history of methotrexate (NSC-740). Cancer Chemotherapy Reports Part 1, 54, 95-101. 

Gehan, E.A. and George, S.L. Estimation of human body surface area from height and weight. Cancer Chemotherapy Reports 1970 54 225-235. 

Source Adapted from Heinerman, J., The Treatment of Cancer with Herbs, BiWorld, Orem, UT, 1980, 1984 as taken from Jonathan L. Hartwell s Plant Remedies for Cancer, Cancer Chemotherapy Reports, 7 19-24, May 1960. 

Hartwell, J.L., Plant Remedies for Cancer, Cancer Chemotherapy Reports, 7 19-24, May... 

S. Banerjee and L. Margulis, Cancer Chemotherapy Reports Part 7, 1971, 55, 531... 

Freireich EJ, Gehan EA, Rail DP et ah (1966). Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey and man. Cancer Chemotherapy Reports, 50 219-44. 

Oncolytic Enzymes. An early report of cancer chemotherapy using an enzyme, pepsin [9001 -75-6] was pubHshed in 1922 (18) its clinical use was surrounded by controversy. 

A total synthesis of (+ )-vinblastine widely used in cancer chemotherapy, has been reported. It includes the synthesis of (-)-vindoline. 1,3-Dipolar cycloaddition of a nitrile oxide has played an important role in the preparation of the indoloazacycloundecane moiety, whose coupling with (-)-vindoline occurs with the desired stereochemistry, leading to an intermediate readily transformed to the target (+ )-vinblastine (492). 

Carter, W.H., Jr. (1985), Response Surface Methodology and the Design of Clinical Trials for the Evaluation of Cancer Chemotherapy, Cancer Treatment Reports, 69, 1049-1053. 

The most frequently reported serious adverse events reported with cancer chemotherapy patients included death, fever, pneumonia, dehydration, vomiting, and dyspnea. The most commonly reported adverse events were fatigue, edema, nausea, vomiting, diarrhea, fever, and dyspnea. The most frequently reported reasons for discontinuation of darbepoetin alfa were progressive disease, death, discontinuation of the chemotherapy, asthenia, dyspnea, pneumonia, Gl hemorrhage, thrombotic events, rash, dehydration. 

Kok T, Lanschot J, Siersema P, et al. Neoadjuvant Chemotherapy in Operable Esophageal Squamous Cell Cancer Final Report of a Phase III Multicenter Randomized Controlled Trial. Proc Am Soc Clin Oncol 1997 16 277a. 

PCR Incorporated (associated with the Schuman-Tarrant group) manufactures 5-fluorouracil by this process for use in cancer chemotherapy and has had annual sales of over a million dollars for the last several years. This fluorination process, which is selective even above room temperature and may be conducted in H20, CF3C02H, or CF3CH2OH, is a curiosity. The selectivity observed at higher temperatures must involve a strong solvent effect rather than being primarily a feature of the fluorination process itself. A report by Cech and Holz describes the fluorination of nitrogenous bases and associated nucleosides to produce 2 -deoxy-5-fluorouridine derivatives (96). This study requires that a saturated room-temperature solution of molecular fluorine in acetic (or tri-... 

In 15 men with osteonecrosis of the femoral head after short-term therapy the mean duration of therapy was 21 (range 7-39) days and the mean dose in milligram equivalents of prednisone was 850 (range 290-3300) mg (269). The time from administration of glucocorticoids to hip pain was 17 (range 6-33) months. A new case of bilateral avascular necrosis of the femoral heads after high-dose short-term dexamethasone therapy as an antiemetic in cancer chemotherapy has been reported (270). 

Analgesics, Drugs Used in Gout), and in cancer (see Chapter 55 Cancer Chemotherapy). Methotrexate may be given orally, subcutaneously, and intramuscularly. Reported oral bioavailability is 50-90% at doses used in chronic inflammatory diseases. Intramuscular and subcutaneous methotrexate exhibit nearly complete bioavailability. 

---